67 WALL STREET, New York - May 2, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation
Companies include: Teva Pharmaceutical Industries (TEVA), Akorn Inc. (AKRX), Allergan Inc. (AGN), Valeant Pharmaceuticals Intern (VRX), Forest Laboratories Inc. (FRX), Salix Pharmaceuticals Ltd. (SLXP), Jazz Pharmaceuticals, Inc. (JAZZ), Mylan, Inc. (MYL), Endo Pharmaceuticals Holdings (ENDP) and many more.
In the following excerpt from the Biotechnology and Pharmaceuticals Report, an expert analyst discusses the outlook for the sector for investors:
TWST: Last time you spoke to us in 2010, you said that in many countries, the use of generic drugs is still limited. Have generics been able to penetrate any markets over the last few years? If so, which countries and which of your companies stand to benefit?
Mr. Amsellem: I think the emerging markets still remain an intriguing area of opportunity for global generic players. The usage of generics in the emerging markets is still not that highly utilized, and certainly the emerging markets have a different generics model than the United States. But the reality is that in the United States, there's a high utilization of generics.
And then in a number of other countries that utilization is not quite the same, so in that sense, you look at Central and Eastern Europe, you look at Latin America, you look at parts of Asia - these are all areas that are fertile ground for continued growth. That aspect of the generic space, I don't think has really changed.
I think if you look at all the big generic players, some of the best topline growth rates, segment growth rates, are coming out of the emerging markets. I think that's likely to continue. I think there are other markets, such as Western Europe, where utilization of generics in specific countries are still not particularly great, but what you have in certain countries in Western Europe are significant pricing pressures.
So to the extent that volume is growing, you've also got significant pricing pressures that blunt some of the impact of higher volumes, so Western Europe is more challenging in that respect. But as you look at Central and Eastern Europe, Latin America, parts of Asia, there's no question that growth should remain fairly strong, at least for the foreseeable future.
TWST: What impact do you expect federal health care reform to have on your group?
For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
- Health Care Industry
- Investment & Company Information